Advanced Filter

Filter by Group

Filter by Market Availability

Displaying all 2 drugs
Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine.[A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than dolutegravir, which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.[A227668,L31193] Cabotegravir was granted FDA approval on...
Approved
Investigational
Matched Description: … combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and ... A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than [dolutegravir ... -1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine
Matched Salts name: … Cabotegravir sodium
Dolutegravir is a HIV-1 intergrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells which gives it an excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV...
Approved
Matched Synonyms: … Dolutegravir
Matched Name: … Dolutegravir
Matched Description: … [L1035] On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of ... [A31342] Dolutegravir was developed by ViiV Healthcare and FDA approved on August 12, 2013. ... The effect of this drug has no homology in human host cells which gives it an excellent tolerability and
Matched Salts name: … Dolutegravir sodium
Matched Categories: … dolutegravir and rilpivirine ... lamivudine and dolutegravir ... lamivudine, abacavir and dolutegravir ... lamivudine, tenofovir disoproxil and dolutegravir ... dolutegravir
Matched Products: … Dolutegravir
Displaying all 2 drugs